GSK PLC (GSK)
33.96
+0.26
(+0.77%)
USD |
NYSE |
Nov 22, 16:00
34.14
+0.18
(+0.53%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 69.29B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 0.31% |
Valuation | |
PE Ratio | 22.08 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 1.763 |
Price to Book Value | 3.696 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.3891 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.146 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 38.66% |
Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV. |
URL | https://www.gsk.com |
Investor Relations URL | https://www.gsk.com/en-gb/investors/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Value |
Next Earnings Release | Feb. 05, 2025 |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Nov. 15, 2024 |
Ratings
Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV. |
URL | https://www.gsk.com |
Investor Relations URL | https://www.gsk.com/en-gb/investors/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Value |
Next Earnings Release | Feb. 05, 2025 |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Nov. 15, 2024 |